Vital Signsby BridgeheadAll voices

01  Voice · Academic · Rare diseases

Hans Quiding: no licensed photograph is held, so the academic plate is shown instead.
Academic

Hans Quiding

Pila Pharma's scientific expert in pain management

Press citations per month · linked articles
1
0
0
0
0
0
0
0
0
0
Feb 2026MarAprMayJuneJulyAugSeptOctNovto date
1

press citation on 1 topic since 12 Feb 2026 · last quoted 12 Feb 2026

02  Quoted on · 1 of 29 topics

Open the topic

Hans Quiding: key facts

Kind of voice
Academic
Role
Pila Pharma's scientific expert in pain management
Quoted on
Rare diseases
Tracked press citations
1
Most recently quoted
12 Feb 2026

04  The signal · where Hans Quiding sits on rare diseases

Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.

Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.

  1. 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
  2. 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
  3. 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
  4. 25=Sneha PatelAcademicClinical Director for Haematology1
  5. 25=Dorte X. GramSector leaderfounder and CSO of Pila Pharma1
  6. 25=Hans QuidingAcademicPila Pharma's scientific expert in pain management1
  7. 25=Dr. Stanley CrookeAcademicFounder of Ionis Pharmaceuticals, CNBC Advisory Board member1
  8. 25=Mary NicholsonSector leaderhead of advocacy at Debra, the national charity for EB1

Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →

05  On the record · press

What Hans Quiding has said

By outlet · linked articles
  • biostock.se1

Where Hans Quiding has been quoted

  1. 01Pila Pharma activates lucrative orphan drug trackbiostock.se · 12 Feb 2026

Verbatim

“I've worked extensively with TRPV1 antagonists for pain management, and I'm very hopeful that this molecule, with its unique safety profile could be of great value for erythromelalgia patients.”
Pila Pharma's scientific expert in pain management · Rare diseases · biostock.se · 12 Feb 2026 · Read the article

Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.